Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'γ)2 antibody

被引:0
作者
Jeffrey S. Bartlett
Jurgen Kleinschmidt
Richard C. Boucher
R. Jude Samulski
机构
[1] Gene Therapy Center,Department of Pharmacology
[2] University of North Carolina at Chapel Hill,undefined
[3] Pulmonary and Cystic Fibrosis Research Center,undefined
[4] University of North Carolina at Chapel Hill,undefined
[5] The Deutsches Krebsforschungszentrum,undefined
[6] University of North Carolina at Chapel Hill,undefined
来源
Nature Biotechnology | 1999年 / 17卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
We have developed a system for the targeted delivery of adeno–associated virus (AAV) vectors. Targeting is achieved via a bispecific F(ab´)2 antibody that mediates a novel interaction between the AAV vector and a specific cell surface receptor expressed on human megakaryocytes. Targeted AAV vectors were able to transduce megakaryocyte cell lines, DAMI and MO7e, which were nonpermissive for normal AAV infection, 70–fold above background and at levels equivalent to permissive K562 cells. Transduction was shown to occur through the specific interaction of the AAV vector–bispecific F(ab´)2 complex and cell–associated targeting receptor. Importantly, targeting appeared both selective and restrictive as the endogenous tropism of the AAV vector was significantly reduced. Binding and internalization through the alternative receptor did not alter subsequent steps (escape from endosomes, migration to nucleus, or uncoating) required to successfully transduce target cells. These results demonstrate that AAV vectors can be targeted to a specific cell population and that transduction can be achieved by circumventing the normal virus receptor.
引用
收藏
页码:181 / 186
页数:5
相关论文
共 180 条
  • [1] Samulski RJ(1993)Adeno–associated virus: integration at a specific chromosomal locus. Curr. Opin. Genet. Dev. 3 74-80
  • [2] Xiao X(1996)Efficient long–term gene transfer into muscle tissue of immunocompetent mice by adeno–associated virus vector. J. Virol. 70 8098-8108
  • [3] Li J(1994)Adeno–associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am. J. Respir. Cell Mol. Biol. 11 517-521
  • [4] Samulski RJ(1994)Long–term expression and phenotypic correction using adeno–associated virus vectors in the mammalian brain. Nat. Genet. 8 148-154
  • [5] Flotte TR(1996)Differential and persistent expression patterns of CNS gene transfer by an adeno–associated virus (AAV) vector. Brain Res. 713 99-107
  • [6] Afione SA(1994)Adeno–associated virus vectors preferentially transduce cells in S phase. Proc. Natl. Acad. Sci. USA 91 8915-8919
  • [7] Zeitlin PL(1993)Stable in vivo expression of the cystic fibrosis transmembrane regulator with an adeno–associated virus vector. Proc. Natl. Acad. Sci. USA 90 10613-10617
  • [8] Kaplitt MG(1996)Safety of single–dose administration of an adeno–associated virus (AAV)–CFTR vector in the primate lung. Gene Ther. 3 658-668
  • [9] Leone P(1994)Recombinant adeno–associated virus (rAAV)–mediated expression of a human g–globin gene in human progenitor–derived erythroid cells. Proc. Natl. Acad. Sci. USA 91 10183-10187
  • [10] Samulski RJ(1994)Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno–associated virus vector. J. Clin. Invest. 94 1440-1448